RDM Healthcare Research Network

“再分布制造”（RDM）被定义为：改变制造业经济和组织的技术、系统和战略，特别是关于位置和规模。2013年11月，EPSRC再分配制造研讨会明确了小规模本地制造（RDM）的潜力及其对英国GDP的贡献。正如研讨会报告所总结的那样，英国工业的成功实施带来了许多挑战和机遇。建立一系列网络来探索和确定这些问题，以及解决这些问题所需的研究议程，是一种及时的方法，可以将多学科社区的专业知识利用到未来连贯的研究倡议中。我们专注于医疗设备和疗法的制造，反映了英国医疗保健的社会经济重要性。NHS在英国的营业额约为1210亿英镑，为大约6400万公民提供服务——技术和服务的边际进步可能会产生巨大影响。医疗保健技术是EPSRC挑战赛的主题。医疗保健网络（RiHN）目标中拟议的RDM将支持EPSRC确定的所有四个战略优先事项（新型治疗和治疗技术；在护理点实时增强的预测和诊断；健康生命过程的技术；以及医疗保健技术的设计、制造和集成）。RDM可以改变医疗保健产品的交付，通过以下方式提高国家竞争力和公民福祉：a)通过终端定制或基于灵活的中间产品的延迟制造来降低成本；b)及时交付，特别是易腐医疗保健产品；c)通过在当地制造中心之间共享支持服务来减少运营管理费用；d)通过向外扩展而不是扩大规模来分配生产，从而管理产能；e)通过建立小型生产单元来应对需求增长，而不是建立单一的大型工厂，从而避免将高额的前期资本成本置于风险之中。实现这些好处的关键挑战是：技术需求必须满足适当的监管标准；必须建立新的培训模式，保持远程操作质量；必须处理社会和人际关系的特点，以提高生活质量，将质量保证纳入业务结构；必须建立新的客户-供应商关系。RiHN的目标是探索这些挑战和激励因素，并将由一个来自制造、管理、人为因素和医疗保健技术的多学科团队领导，结合社会科学和工程所需的专业知识。该联盟在主要国家网络和研究中心的交付方面具有经验，并将建立在该团队与行业、临床网络、NHS、监管机构、政策制定者、学者和最终用户的既定关系之上。RiHN旨在制定医疗保健领域RDM的研究议程，通过研讨会和用户参与活动与相关学术和用户社区合作，并在五个不同领域开展可行性研究：医疗设备;2. 药品;3. 高级治疗学（细胞和组织）；4. 牙科的;5. 诊断。在此过程中，RiHN打算在医疗保健领域建立一个RDM实践社区，概述未来的研究方向，并将在白皮书中发布。RiHN的产出也将通过网站、在有关的国家和国际会议上的发言、参加其他RDM网络活动和研究中心以及发表可行性研究结果的特刊（业务管理杂志）来传播。最终报告将以电子方式发送给所有感兴趣的各方，并在RiHN的网站上提供。

'Re-distributed manufacture' (RDM) is defined as: Technology, systems and strategies that change the economics and organisation of manufacturing, particularly with regard to location and scale. The potential for smaller-scale local manufacturing (RDM) and its contribution to UK GDP was made clear at the EPSRC Re-Distributed Manufacturing Workshop in November 2013. As the Workshop report concluded, successful implementation in UK industry presents many challenges and opportunities. The creation of a series of Networks to explore and define these issues, and the research agenda required to resolve them, is a timely approach to harnessing the expertise of a multidisciplinary community into a future coherent research initiative.Our focus on manufacture of healthcare devices and therapies reflects the socio-economic importance of healthcare within the UK. The NHS has a turnover of some £121bn in the UK and serves a population of around 64m citizens - marginal advances in technology and services can have large impacts. Healthcare technologies are an EPSRC Challenge theme. The proposed RDM in Healthcare Network's (RiHN) objectives will support all four of the strategic priorities identified by EPSRC (novel treatment and therapeutic technologies; enhanced prediction and diagnosis in real time at the point-of-care; technologies for a healthy life course; and design, manufacture and integration of healthcare technologies). RDM may change the delivery of healthcare products, enhancing national competitiveness and citizen well-being through: a) Cost reduction through terminal customisation or delayed manufacture based upon flexible intermediate products; b) Just-in-time delivery, particularly of perishable healthcare goods, c) Reduction of operational overheads by sharing support services between local manufacturing hubs, d) Management of capacity by distributing production through scale-out, rather than scale-up, e) Avoidance of placing high up-front capital cost at risk by building small production units in response to increase in demand instead of single large factories.There are key challenges to realising these benefits: Technical needs must meet the appropriate regulatory standard; new training patterns must be established to maintain operating quality from a distance; social and inter-personal features must be addressed to enhance quality of life, incorporating quality assurance into the business structures; new customer-supplier relationships must be forged. RiHN aims to explore these challenges and incentives and will be led by a multi-disciplinary team drawn from manufacturing, management, human factors and healthcare technologies, combining the expertise required from both the social sciences and engineering. The consortium has experience in delivery of major national networks and research centres and will build on the established relationships that the team have with industry, clinical networks, the NHS, regulatory bodies, policy-makers, academics and end users.RiHN aims to develop the research agenda for RDM in healthcare, engaging with relevant academic and user communities through workshops and user engagement events, and through conducting feasibility studies in five distinct areas: 1. Medical Devices; 2. Pharmaceuticals; 3. Advanced Therapeutics (cell and tissue); 4. Dentistry; 5. Diagnostics. In doing so, RiHN intends to establish a community of practice for RDM in Healthcare, outlining the future direction for research, which will be published in a white paper. The outputs of RiHN will also be disseminated through a website, presentations at relevant national and international conferences, participation at other RDM Network events and research centres and a Special Issue journal (Journal of Operations Management) presenting the findings of the feasibility studies. A final report will be produced, sent electronically to all interested parties, and made available on RiHN's website.